Nav: Home

Antidepressant effects of ketamine

December 08, 2016

New preclinical evidence was put forward by investigators in a series of presentations at the recent meeting of the American College of Neuropsychopharmacology suggest that the a metabolite of ketamine can produce antidepressant-like effects in a mouse model of depression. The metabolite is produced when ketamine is broken down in the body. This finding may lead to further research to better understand ketamine's efficacy in depression and its potential side effects.

Recent findings show that ketamine, which is used in both human and veterinary medicine as an anesthetic, has rapid and potent antidepressant effects in humans, even in those resistant to the beneficial effects of more traditional antidepressants. This finding has raised hope that ketamine may represent a new treatment option to help those suffering from the debilitating symptoms of depression. However, ketamine has euphoric effects which have been associated with abuse potential - though typically at much higher doses than are used to treat depression. Ketamine can also induce dream-like states and perceptual changes. This has sparked a race to better understand how ketamine may contribute to anti-depressant effects, and to determine whether potential side effects can be separated from its beneficial antidepressant effects.

Ketamine is composed of two different isomers, called R-ketamine and S-ketamine, which are mirror images of each other. These two components of ketamine are converted in the body into R- and S-metabolites that, potentially, can have different actions. In his presentation, Dr. Kenji Hashimoto showed that in rodents, the antidepressant-like behavioral effects of ketamine may be related to the actions of R-ketamine and ketamine metabolites. Remarkably, one of these metabolites, S-norketamine, demonstrated in rodents that antidepressant-like effects in the absence of the motor stimulation effects which may be seem after ketamine treatment or recreational use. In a related presentation, Dr. Irving Wainer showed that another ketamine metabolite, hydroxynorketamine (HNK), also has potent antidepressant effects but does not show motor stimulation effects. It should be noted that the observations were in animal studies, which are not necessarily reproducible in humans. Additional studies in humans are needed to better understand the efficacy and safety of R-ketamine, S-norketamine and other ketamine metabolites in humans.

Dr Jaz Singh presented clinical data from a phase 2 study with intranasal S-ketamine showing a dose response in depressed humans who had not responded to conventional antidepressant drugs, and the efficacy persisted for 8 weeks after the last dose. Dissociative effects were dose dependent, began shortly after start of dosing, resolved in < 2 hours, and significantly attenuated with multiple dosing.

Finally, Dr. Lisa Monteggia provided new insights into how ketamine may act in the brain to exert antidepressant effects. She showed that ketamine activates the production of new proteins in nerve cells. These proteins play a role in encoding new memories and other information by brain cells. This suggests that ketamine may improve the function of brain circuits involved in mood regulation.

These findings suggest that R-norketamine, HNK and other closely related drugs could have antidepressant effects like those of ketamine but without its negative side effects. The findings also suggest that drugs that modify the ability of brain cells to produce new proteins could represent an entirely new class of antidepressant drugs.
-end-
Presenters: Lisa Monteggia, Ph.D.
Kenji Hashimoto, Ph.D.
Jaskaran Singh, M.D.
Edward Domino, M.D., M.S.

American College of Neuropsychopharmacology

Related Depression Articles:

Tackling depression by changing the way you think
A thought is a thought. It does not reflect reality.
How depression can muddle thinking
Depression is associated with sadness, fatigue and a lack of motivation.
Neuroimaging categorizes 4 depression subtypes
Patients with depression can be categorized into four unique subtypes defined by distinct patterns of abnormal connectivity in the brain, according to new research from Weill Cornell Medicine.
Studies suggest inflammatory cytokines are associated with depression and psychosis, and that anti-cytokine treatment can reduce depression symptoms
Studies presented at this year's International Early Psychosis Association meeting in Milan, Italy, (Oct.
Is depression in parents, grandparents linked to grandchildren's depression?
Having both parents and grandparents with major depressive disorder was associated with higher risk of MDD for grandchildren, which could help identify those who may benefit from early intervention, according to a study published online by JAMA Psychiatry.
Postpartum depression least severe form of depression in mothers
Postpartum depression -- a household term since actress Brooke Shields went public in 2005 about her struggle with it -- is indeed serious.
Tropical Depression 1E dissipates
Tropical Depression 1E or TD1E didn't get far from the time it was born to the time it weakened to a remnant low pressure area along the southwestern coast of Mexico.
Diagnosing depression before it starts
MIT researchers have found that brain scans may identify children who are vulnerable to depression, before symptoms appear.
Men actually recommend getting help for depression
Participants in a national survey read a scenario describing someone who had depressed symptoms.
Depression too often reduced to a checklist of symptoms
How can you tell if someone is depressed? The Diagnostic and Statistical Manual of Mental Disorders (DSM) -- the 'bible' of psychiatry -- diagnoses depression when patients tick off a certain number of symptoms on the DSM checklist.

Related Depression Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...